Scientists Finger A Molecular Kingpin In Body's Response To Cigarettes

November 23, 1998

Using genetically modified "knock-out" mice, scientists at the University of Rochester have produced the strongest evidence yet implicating a specific gene -- the same one that makes us susceptible to the pollutant dioxin -- as a vital link in the chemical cascade whereby cigarette smoke causes cancer. The finding comes thanks to a batch of genetically engineered mice normal in every way except for the deletion of the gene for the aromatic hydrocarbon, or AH, receptor; these mice had no damage from the same levels of cigarette smoke that caused significant gene damage in their normal brethren.

The work, reported in the November issue of Carcinogenesis, clarifies how cigarette smoke has an impact on our molecular machinery and should help researchers in their efforts to prevent genetic damage from the biochemical assault posed by smoking.

The team at the University's Environmental Health Science Center cautions that researchers must perform longer-term, larger studies and check in additional ways for evidence of gene damage to understand precisely how cigarette smoke damages our DNA, including the AH receptor's role. However, "It's quite possible that the AH receptor is one of the body's master switches that governs those pathways that control much of the gene damage from cigarette smoke," says principal author Tom Gasiewicz, professor of environmental medicine.

With every breath of cigarette smoke, the body is confronted by more than 4,000 chemicals; animals like humans and mice break some down into harmless byproducts and turn others into more dangerous compounds that wreak havoc throughout the body, breaking up or binding to our DNA and turning on or off important genes. Cancer typically develops because of such damage to several genes. While scientists have long known that every puff of cigarette smoke causes a molecular melee that plays a role in one-third of all cases of cancer, sorting out the primary culprits has been difficult.

Enter the dioxin research group headed by Gasiewicz, an internationally recognized expert on dioxin who occasionally sports a cap embossed with the words, "Team Dioxin." The chemical is now found in low levels in all animals, including humans; it enters the body mainly through the foods we eat, with its ultimate source in the production of plastics and electronic equipment, herbicides, and combustion from automobiles, power plants and incinerators.

For two decades Gasiewicz has studied how dioxin binds to and manipulates the AH receptor, which plays a key role in determining how our body reads its DNA and controls many genes. Graduate student Stephen Dertinger, who had recently helped develop a technique that uses lasers to assess gene damage while working at Litron Laboratories, suggested taking a look at the effects of cigarette smoke, which counts dioxin-like compounds among its constituents. So the team set out, with funding from the National Institute of Environmental Health Sciences.

Gasiewicz and Dertinger studied "knock-out" mice, animals that scientists have especially crafted for research by deleting a specific stretch of DNA. These mice were supplied by long-time collaborator Allen Silverstone of the SUNY Health Science Center in Syracuse; the animals trace their lineage back to the National Cancer Institute, whose researchers were the first to knock out the AH receptor. For three days the team exposed 20 young adult mice to the equivalent amount of smoke particulates that a human receives from smoking six or seven cigarettes a day.

"These animals were exposed to the same complex mixture of chemicals found in cigarette smoke, not just one highly purified chemical constituent. This is a more realistic model of exposure and is an important distinction between this and many other studies," says Dertinger. After exposure the team analyzed each animal's blood cells, using a laser to measure gene damage faster and with greater sensitivity than conventional microscope-based methods.

While normal mice showed significant amounts of gene damage, mice without the AH receptor showed none. "We were very surprised. This suggests that the genes responsible for DNA damage from cigarettes are controlled predominantly by this receptor," says Gasiewicz.

Gasiewicz and Dertinger note that the result covers only one type of gene damage in a single type of tissue. Specifically, the team measured chromosome breaks in blood cells created in the bone marrow. The team plans to study damage in other tissues, such as the liver and lungs. Gasiewicz also says that longer-term studies to look for some of the ultimate products of damaged genes -- tumors -- are necessary.

"Our results show that the AH receptor definitely plays an important role, but more work is necessary before we conclude that it's the most important factor mediating genetic damage from cigarettes," adds Dertinger.

The findings complement recent work by other researchers who have shown that people with an abundance of enzymes known as CYP1A1 or P450 cytochrome molecules are more prone to developing cancer from smoking. The AH receptor turns on these enzymes, and it's long been considered a prime suspect in smoking-related gene damage; a few years ago a team from the University of California at Davis showed in the laboratory that the receptor seems to play an important role in the process. The Rochester team's results are the first to demonstrate the link so dramatically in animals.

"This is a significant study," says Gary Gairola, research professor in the College of Pharmacy at the University of Kentucky and an expert on cigarette smoke toxicology. "The team has used a clear endpoint, micronucleus formation, to cleverly demonstrate the role of the AH receptor in cigarette smoke-induced genetic damage."

The team also discovered a synergistic effect between cigarette smoke and dioxin-like chemicals: The more that such chemicals bind to the AH receptor, the more the receptor churns out enzymes that make cigarette smoke harmful to our bodies. "It's a double whammy," says Gasiewicz: "The dioxins now present in our environment may strengthen cigarettes' cancerous kick."

Intimate knowledge of the molecular targets of cigarette smoke suggests an intriguing line of research: a smoking vaccine, a compound that would somehow protect against the ravages of tobacco smoke. The team has published several papers on designs of AH receptor antagonists, molecules that would tie up the body's receptors and make the body immune to chemicals in cigarette smoke that target the receptor. The team's compounds are very similar to molecules known as "flavonoids" found in foods like broccoli, cabbage and soybeans, all known cancer fighters.

"We all know people who smoked their whole lives but never got lung cancer," says Gasiewicz. "One of the reasons may be differing amounts of receptors such as the AH receptor. Or those people may be exposed to drugs or chemicals in their diet, similar to the antagonists we're designing, that alter the metabolism of cigarette smoke.

"Of course, the best way to limit the harmful effects of cigarette smoke is to avoid exposure completely. Don't smoke: It's that simple."
-end-


University of Rochester

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.